|
|
| Line 1: |
Line 1: |
| {{Drugbox
| |
| | IUPAC_name = 4-[5-[Bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
| |
| | image = Bendamustine.png
| |
| | CAS_number =
| |
| | CAS_supplemental =
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem = 65628
| |
| | DrugBank =
| |
| | C = 16 | H = 21 | Cl = 2 | N = 3 | O = 2
| |
| | molecular_weight = 358.262 g/mol
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = D
| |
| | pregnancy_category=
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = Rx-only
| |
| | routes_of_administration = [[Intravenous therapy|Intravenous]]
| |
| | licence_US =Treanda
| |
| }}
| |
| {{SI}}
| |
| {{CMG}}
| |
|
| |
|
|
| |
|
| |
| ==Overview==
| |
| '''Bendamustine''' ([[International Nonproprietary Name|INN]], ''tradenames Ribomustin and Treanda'') is a substance in the treatment of [[cancer]]. It belongs to the family of drugs called alkylating agents. It is also called SDX-105.
| |
|
| |
| ==History==
| |
| Bendamustine received its first marketing approval in Germany, which is marketed under the tradename Ribomustin, by Astellas Pharma GmbH's licensee, Mundipharma International Corporation Limited, which it is indicated as a single-agent or in combination with other anti-cancer agents for indolent NHL, multiple myeloma, and CLL. SymBio Pharmaceuticals Ltd holds exclusive rights to develop and market bendamustine HCl in Japan and selected Asia Pacific Rim countries.
| |
|
| |
| On March 20, 2008, [[Cephalon]] received approval from the [[United States]] [[Food and Drug Administration]] to market bendamustine in the US, where it is sold under the tradename Treanda.<ref>{{cite web |url=http://www.cephalon.com/newsroom/news_reader.aspx?ID=1120688 |title=Cephalon press release - Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia |accessdate=2008-03-23 |format= |work= }}</ref> Bendamustine is the first drug approved for patients with CLL in the US since 2001.
| |
|
| |
| ==References==
| |
| {{Reflist}}
| |
|
| |
| {{Chemotherapeutic agents}}
| |
|
| |
| [[Category:Chemotherapeutic agents]]
| |
| [[Category:Benzimidazoles]]
| |
|
| |
| {{WH}}
| |
| {{WS}}
| |